GRFSライブシグナル | Getagraph.comで利益を最大化

買う 108025 min ago

@ $8.53

発行日: 15 2月 2024 @ 01:16

リターン: -24.15%

前回のシグナル: 2月 14 - 02:31

前回のシグナル: 売る

リターン: 1.67 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:42):

Stats
本日の出来高	836 888
平均出来高	2.15M
時価総額	5.49B
EPS	$0.140 ( 2024-03-05 )
Last Dividend	$0.456 ( 2021-06-03 )
Next Dividend	$0 ( N/A )
P/E	64.70
ATR14	$0.00900 (0.14%)

ボリューム相関

長: -0.09 (neutral)

短: -0.99 (very strong negative)

Signal:(46.89) Neutral

Grifols S.A. 相関

10 最も正の相関
NETE	0.949
MMAC	0.937
TKNO	0.911
STRA	0.907
AMRB	0.897
VTRS	0.891
WLDN	0.89
TRUE	0.889
GRAB	0.887
HOLX	0.885

10 最も負の相関
SVAC	-0.951
PAIC	-0.935
RMRM	-0.93
SVOK	-0.91
TLGT	-0.906
MTSL	-0.873
CNET	-0.865
FTOC	-0.861
FVE	-0.857
FEYE	-0.854

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Grifols S.A. 相関 - 通貨/商品

-0.24
( neutral )

-0.55
( weak negative )

0.00
( neutral )

-0.17
( neutral )

0.85
( strong )

-0.48
( neutral )

Grifols S.A. 財務諸表

Annual	2023
収益:	$6.59B
総利益:	$2.32B (35.24 %)
EPS:	$0.0873

FY	2023
収益:	$6.59B
総利益:	$2.32B (35.24 %)
EPS:	$0.0873

FY	2022
収益:	$6.06B
総利益:	$2.23B (36.80 %)
EPS:	$0.310

FY	2021
収益:	$4.93B
総利益:	$1.96B (39.78 %)
EPS:	$0.270

Financial Reports:

No articles found.

Grifols S.A. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Grifols S.A. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 5.88 - average (63.08%) | Divividend Growth Potential Score: 1.372 - No dividend growth expected in the near future

Information

First Dividend	$0.00650	2013-05-29
Last Dividend	$0.456	2021-06-03
Next Dividend	$0	N/A
Payout Date	2021-06-14
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	$3.04	--
Avg. Dividend % Per Year	0.38%	--
Score	1.9	--
Div. Sustainability Score	5.88
Div.Growth Potential Score	1.372
Div. Directional Score	3.63	--

Next Divdend (Est)
(2024-08-26)

$0 Estimate 0.00 %

Dividend Stability

0.07 Very Bad

Dividend Score

1.90

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2013	$0.136	1.06%
2014	$0.301	1.72%
2015	$0.353	2.05%
2016	$0.350	2.19%
2017	$0.375	2.33%
2018	$0.479	2.05%
2019	$0.394	2.18%
2020	$0.201	0.85%
2021	$0.456	2.41%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0251	1.500	9.50	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00769	1.200	9.74	10.00	[0 - 0.3]
returnOnEquityTTM	0.0279	1.500	-0.801	-1.202	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.79	0.800	1.069	0.855	[1 - 3]
quickRatioTTM	0.629	0.800	-1.006	-0.805	[0.8 - 2.5]
cashRatioTTM	0.229	1.500	9.84	10.00	[0.2 - 2]
debtRatioTTM	0.425	-1.500	2.92	-4.38	[0 - 0.6]
interestCoverageTTM	2.33	1.000	-0.248	-0.248	[3 - 30]
operatingCashFlowPerShareTTM	0.307	2.00	9.90	10.00	[0 - 30]
freeCashFlowPerShareTTM	-0.0538	2.00	-0.0269	-0.0538	[0 - 20]
debtEquityRatioTTM	1.564	-1.500	3.74	-5.62	[0 - 2.5]
grossProfitMarginTTM	0.381	1.000	6.99	6.99	[0.2 - 0.8]
operatingProfitMarginTTM	0.135	1.000	9.30	9.30	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.0229	1.000	-0.984	-0.984	[0.2 - 2]
assetTurnoverTTM	0.306	0.800	-1.291	-1.033	[0.5 - 2]
Total Score				5.88

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	24.48	1.000	7.63	0	[1 - 100]
returnOnEquityTTM	0.0279	2.50	-0.515	-1.202	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.0538	2.00	-0.0179	-0.0538	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.307	2.00	9.90	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.413	1.500	-0.582	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0317	1.000	-1.708	0	[0.1 - 0.5]
Total Score				1.372

Grifols S.A.

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.